Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 411-760-1 | CAS number: 116633-53-5 COMMERCIAL DRAGON II
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1991-1993
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: In accordance with GLP and similar to OECD protocol 427.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Report date:
- 1993
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 427 (Skin Absorption: In Vivo Method)
- GLP compliance:
- yes
Test material
- Reference substance name:
- Bis(N,N',N''-trimethyl-1,4,7-triazacyclononane)-trioxo-dimanganese (IV) di(hexafluorophosphate)monohydrate
- EC Number:
- 411-760-1
- EC Name:
- Bis(N,N',N''-trimethyl-1,4,7-triazacyclononane)-trioxo-dimanganese (IV) di(hexafluorophosphate)monohydrate
- Cas Number:
- 116633-53-5
- Molecular formula:
- C18 H42 Mn2 N6 O3 . 2 F6 P
- IUPAC Name:
- dimanganese(4+) bis(1,4,7-trimethyl-1,4,7-triazonane) bis(hexafluoro-λ⁵-phosphanuide) hydrate trioxidandiide
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- The [14C]Mn Catalyst was synthesised in the Radiochemical Section at URL Vlaardingen, Netherlands, a non-GLP compliant laboratory but a competent radiochemical laboratory. The radiochemical purity of the sample had not been determined but a specific activity of 9.lµCi/mg was quoted (URLV data).
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- other: Olac Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 166 ± 6g (male) and 148 ± 7g (female)
- Fasting period before study: unknown
- Housing: rats were housed in individually-labelled metabolism cages specifically designed for the collection of urine, faeces and expired air for 14C analysis .
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: Dorsal hair was removed with clippers from all rats at 24 hours prior to treatment.
IN-LIFE DATES: Between 23rd July and 25th July 1991.
Each rat was then placed in its individual metabolism cage and control (background) urine and faeces samples were collected and, immediately before treatment, control samples of C02 absorber were also collected.
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- other: 50% aqueous ethanol
- Duration of exposure:
- 48 hours
- Doses:
- Thin layer chromatography (TLC) was carried out on the test solution to demonstrate the stability of the [14C]Mn Catalyst over the dosing period.
The topically applied dose was 95µg/cm 2.
Topically treated male and female rats received 0.95mg (8.7µCi) of [14C]Mn Catalyst over 9.62 cm2 of clipped skin with occlusion. - No. of animals per group:
- 4 male amd 4 female rats
- Control animals:
- no
- Details on study design:
- Topical application of [ 14C]Mn Catalyst: Immediately prior to dosing, the rats were anaesthetised with cyclopropane and a rubber 0-ring of 35mm internal diameter was attached to the dorsal skin with Permabond superglue. Each rat was then treated topically with 100µ1 of test solution which was spread over the 9.62 cm2. The treated area was then dried using a hair dryer and a rubber disc of 38mm diameter mounted onto the 0-ring with the superglue to provide an occlusive cover.
All cages were fitted with absorption towers containing ethanolamine: 2-methoxyethanol (1:2 by volume) for the collection of expired 14C02. Samples of trapped expired air were assayed for radioactivi ty content at intervals of 4, 8, 24 and 48 hours. Urine was collected at 8, 24 and 48 hours and faeces at 24 and 48 hours. At 48 hours the rats were killed by gaseous anesthetic when the protective device was removed and cut into small pieces ready for solvent extraction.The rats were then reweighed.
The treated skin site with a 1 cm border was excised and rinsed with approximately 20ml of 50% aqueous ethanol . The skin and the rinsings were both analysed for 14C.The carcass remains were prepared for 14C analysis.The cages and excreta separators were rinsed down with distilled water and the rinsings analysed for 14C.
Analysis of 14C
Throughout the study 14C activity was determined by liquid scintillation counting. Samples were counted in a Beckman LS3800 spectrometer using Liquiscint (National Diagnostics, Aylesbury, England) as the scintillation cocktail except for the C02 absorber and faeces samples
The urine samples were made up to a suitable volume with distilled water (e.g. l0ml or 25ml). Triplicate aliquots of 0.5ml were counted in l0ml of liquiscint.
The 14C content of the faeces was determined by freeze drying and then weighing, pelleting and combusting duplicate samples of about 300mg in a sample oxidiser using C02 absorber and scintillator.
The protective devices were extracted twice at room temperature in 50ml of 50% aqueous ethanol and triplicate 0.S ml aliquots assayed for radioactivity in l0ml of Liquiscint.
The skin rinsings were weighed and triplicate 0.5ml aliquots counted in l0 ml of Liquiscint.
Excised skins were dissolved overnight at 60°C in 25ml of Soluene-350 tissue solubiliser and triplicate 0.5ml aliquots assayed for radioactivity in l0 ml of liquiscint following the addition of three drops of glacial acetic acid to each sample.
Carcasses were solubilised in 250ml of 10% sodium hydroxide overnight at 60°C. To the digest was added 50ml of concentrated hydrochloric acid and the total volume was adjusted to l000 ml with 250ml of ethanol and water. Triplicate 1.0ml aliquots were then assayed for radioactivity in 15ml of Liquiscint.
The 14C content in the cage washings was analysed by making the cage wash volume up to 50ml in distilled water and counting triplicate 0.5ml aliquots in lOml of Liquiscint.
During the course of the treatments dose equivalents were made up to 250ml with ethanol.Five aliquots of 0.5ml were counted in l0 ml of Liquiscint to determine the amount of radioactive test material dosed to each rat.
Thin layer chromatographic (TLC) analysis of the test solution, urine, test site washings, and extract of a protective device. Two TLC systems used were :
1. Polygram silica gel G plates developed in chloroform: methanol:water (65:25:4 by volume).( known as system 1)
2. KC18 reverse phase plates developed in 0.29M ammonium dihydrogen orthophosphate: acetonitrile: methanol (60:28:12 by volume) - HPLC (due to the fact that this system was recommended for high performance liquid chromatographic separation of Manganese Catalyst).(known as system 2).
Results and discussion
- Signs and symptoms of toxicity:
- no effects
- Remarks:
- (male) and from 148 ± 7g to 136 ± llg (female)
- Dermal irritation:
- no effects
- Absorption in different matrices:
- When [14C]Mn Catalyst was applied to male and female rat skin in an aqueous ethanolic solution and left in contact under occlusive conditions for 48 hours, a proportion of the 14C dose penetrated the skin as shown by the presence of 14C in excreta and tissues of the rat.The main route of excretion was in the urine although approximately 1% of the applied dose was in the carcasses at 48 hours.
The topically applied dose was 95µg/cm 2 and during 48 hours penetration through male rat skin was 2.3% to 17.5% and 0.6% to 4.9% through female rat skin.There was a significant difference between the sexes in the fate of [14C]Mn Catalyst. Significant amounts (between 5 and 35% of the 14C dose) were transferred from skin to the protective device during 48 hours which may have reduced the amount of 14C available for percutaneous absorption.
The predominant route of excretion was in the urine. TLC of the rinsings showed that {14C]Mn Catalyst was unstable on the skin
- Skin wash: Some 14% (male) and 27% (female) of the dose was rinsed from the skin at 48 hours
- Skin test site: Some 51% (male) and 41% (female) was retained on the skin.
- Carcass: 48 hours - 1.0% (male) and 0.7% (female)
- Urine: 6.5% (male) and 1.3% (female) from mean absorption values of some 8.7% and 2.7% respectively.
- Cage wash + cage wipe: inclusion of 14C recoveries from cage rinsings, possibly originating from urinary contamination, increased these urine values to some 6.6% and 1.7% respectively.
-:Protective device: Carbon-14 extracted from the protective device amounted to some 12% (male) and 22% (female) of the dose.
The wide variation between the groups of rats in the levels of percutaneously absorbed 14C may possibly be due to several parameters. The test solution used in these experiments was without added perborate which is included in the commercial product to stabilise the Mn Catalyst. Also the the variable conditions of pH which occur on skin and the presence of the adhesive on the protective device was thought to support the degradation of Mn Catalyst to the free ligand. - Total recovery:
- Thin layer chromatography
In system 1 the bulk of the urinary radioactivity was confined to a single region with three other minor radioactive regions separated from the urine. Also in system 1, the major impurity in the [14C]Mn Catalyst marker in control urine now had an Rf value of 0.22.
In system 2 the urine sample contained one major region of radioactivity. This region coincided with the major impurity in the [14C]Mn Catalyst in control urinE . In control urine the [14C]Mn Catalyst had an Rf value of 0.59.
Autoradiograms of TLC separations of an aliquot of skin washings which were developed in systems 1 and 2 and two major regions of radio activity were separated by both systems which are probably the Mn Catalyst and the free ligand.This indicates that reduction of the [14C]Mn Catalyst has probably occurred on the skin.
Percutaneous absorptionopen allclose all
- Dose:
- 95µg/cm2
- Parameter:
- percentage
- Absorption:
- ca. 0.6 - ca. 4.9 %
- Remarks on result:
- other: 48 hrs
- Remarks:
- 2.64 ± 1.98 µg/cm2 through female rat skin
- Dose:
- 95µg/cm2
- Parameter:
- percentage
- Absorption:
- ca. 2.3 - ca. 17.5 %
- Remarks on result:
- other: 48 hrs
- Remarks:
- 8.66 ± 6.23 µg/cm through male rat skin
Applicant's summary and conclusion
- Conclusions:
- After topical application of [14C]Mn Catalyst to rat skin under conditions of occulusion a considerable proportion of the 14C dose was absorbed through skin.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.